Ocumension Therapeutics Wins China Nod for Eye Inflammation Drug
Ocumension Therapeutics (HKG:1477) received approval from China's National Medical Products Administration for the new drug application of OT-502, according to a Thursday Hong Kong bourse filing. OT-502, marketed as DEXYCU and Shishu, is a single-dose, sustained-release dexamethasone intraocular suspension indicated for the treatment of postoperative ocular inflammation.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.